Should I buy or sell Kinnate Biopharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares. View KNTE analyst ratings or view top-rated stocks .

What is Kinnate Biopharma's stock price target for 2024?

5 brokerages have issued 1 year price objectives for Kinnate Biopharma's stock. Their KNTE share price targets range from $2.00 to $24.00. On average, they anticipate the company's stock price to reach $8.15 in the next twelve months. This suggests a possible upside of 207.5% from the stock's current price. View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts .

How have KNTE shares performed in 2024?

Kinnate Biopharma's stock was trading at $2.37 on January 1st, 2024. Since then, KNTE shares have increased by 11.8% and is now trading at $2.65. View the best growth stocks for 2024 here .

When is Kinnate Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KNTE earnings forecast .

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73).

When did Kinnate Biopharma IPO?

Kinnate Biopharma (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (2.20%). Insiders that own company stock include Carl L Gordon , James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams. View institutional ownership trends .

How do I buy shares of Kinnate Biopharma?

Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free KNTE Stock Alerts

$2.65

-0.01 (-0.38%)

(As of 04/3/2024)

Compare

Today's Range: $2.64
▼
$2.68
50-Day Range: $2.24
▼
$2.66
52-Week Range: $1.04
▼
$7.18

Volume: 2.81 million shs
Average Volume: 418,678 shs
Market Capitalization: $125.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.72

Get Kinnate Biopharma alerts:

Kinnate Biopharma MarketRank™ Stock Analysis

Analyst Rating: Hold
2.17 Rating Score
Upside/Downside: 207.5% Upside
$8.15 Price Target
Short Interest: Healthy
2.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.51) to ($1.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

103rd out of 918 stocks

Biotechnology Industry

1st out of 15 stocks

3.0

Analyst's Opinion

Consensus Rating
Kinnate Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kinnate Biopharma has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.01% of the float of Kinnate Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Kinnate Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kinnate Biopharma has recently decreased by 43.56%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Kinnate Biopharma does not currently pay a dividend.
Dividend Growth
Kinnate Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kinnate Biopharma has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Kinnate Biopharma is -0.81.

0.6

News and Social Media Coverage

Search Interest
2 people have searched for KNTE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Kinnate Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kinnate Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.70% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.89% of the stock of Kinnate Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kinnate Biopharma are expected to grow in the coming year, from ($2.51) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kinnate Biopharma has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

KNTE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KNTE Stock News Headlines

April 5, 2024 | seekingalpha.com

KNTE Kinnate Biopharma Inc.

March 13, 2024 | businesswire.com

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 1, 2024 | msn.com

Kinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratories

March 1, 2024 | markets.businessinsider.com

Kinnate Biopharma Sells Exarafenib To Pierre Fabre Laboratories - Quick Facts

March 1, 2024 | prnewswire.com

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

March 1, 2024 | globenewswire.com

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

February 19, 2024 | businesswire.com

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 17, 2024 | realmoney.thestreet.com

Kinnate Biopharma just downgraded at William Blair, here's why

February 17, 2024 | finance.yahoo.com

Private equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as well

February 16, 2024 | prnewswire.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.

February 16, 2024 | prnewswire.com

Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA

February 16, 2024 | businesswire.com

KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders

February 16, 2024 | businesswire.com

KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders

February 16, 2024 | finance.yahoo.com

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

February 16, 2024 | globenewswire.com

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

December 12, 2023 | seekingalpha.com

Kinnate Biopharma: Righting The Ship, But Still Not The Right Time (Rating Upgrade)

November 24, 2023 | finance.yahoo.com

Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors

November 15, 2023 | msn.com

Why is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?

November 15, 2023 | finance.yahoo.com

OrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma Inc

November 9, 2023 | finance.yahoo.com

Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

October 4, 2023 | theglobeandmail.com

Instrument Name Kinnate Biopharma Inc Instrument Symbol (KNTE-Q)

October 3, 2023 | finance.yahoo.com

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

September 20, 2023 | msn.com

Jefferies Maintains Kinnate Biopharma (KNTE) Buy Recommendation

September 19, 2023 | msn.com

Bay Area biotech company Kinnate to lay off 70% of workforce

September 19, 2023 | msn.com

Wedbush Downgrades Kinnate Biopharma (KNTE)

See More Headlines

Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/11/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:KNTE
CUSIP: N/A
CIK: 1797768
Web: www.kinnate.com
Phone: 858-299-4699
Fax: N/A
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.15
High Stock Price Target: $24.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +342.2%
Consensus Rating: Hold
Rating Score (0-4): 2.17
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-116,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -62.31%
Return on Assets: -54.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.80
Quick Ratio: 10.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.06 per share
Price / Book: 0.52

Miscellaneous

Outstanding Shares: 47,220,000
Free Float: 27,532,000
Market Cap: $125.13 million
Optionable: Optionable
Beta: 1.38

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Nima Farzan M.B.A. (Age 48)
President, CEO & Director
Comp: $891.95k
Ms. Neha Krishnamohan (Age 36)
CFO, Principal Accounting Officer and Executive VP of Corporate Development
Comp: $548.95k
Mr. Mark A. Meltz (Age 50)
COO, General Counsel, Treasurer & Secretary
Comp: $671.86k
Dr. Richard Thomas Williams MBBS (Age 55)
Ph.D., Chief Medical Officer
Dr. Robert Kania Ph.D.
Senior Vice President of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KNTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Kinnate Biopharma stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares.
View KNTE analyst ratings or view top-rated stocks.
What is Kinnate Biopharma's stock price target for 2024?: 5 brokerages have issued 1 year price objectives for Kinnate Biopharma's stock. Their KNTE share price targets range from $2.00 to $24.00. On average, they anticipate the company's stock price to reach $8.15 in the next twelve months. This suggests a possible upside of 207.5% from the stock's current price.
View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts.
How have KNTE shares performed in 2024?: Kinnate Biopharma's stock was trading at $2.37 on January 1st, 2024. Since then, KNTE shares have increased by 11.8% and is now trading at $2.65.
View the best growth stocks for 2024 here.
When is Kinnate Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KNTE earnings forecast.

How were Kinnate Biopharma's earnings last quarter?: Kinnate Biopharma Inc. (NASDAQ:KNTE) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73).
When did Kinnate Biopharma IPO?: Kinnate Biopharma (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.
Who are Kinnate Biopharma's major shareholders?: Kinnate Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (2.20%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams.
View institutional ownership trends.
How do I buy shares of Kinnate Biopharma?: Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNTE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial